The next meeting of the National Drug Scheduling Advisory Committee (NDSAC) is scheduled for March 5, 2023. The primary purpose of the meeting is to consider the following matter:
- Request for Unscheduled status for loratadine and its salts and preparations in products marketed for pediatric use in children aged 2 to 11 years
Individuals, companies or organizations seeking Interested Party status for this agenda item are invited to complete the Interested Party Application Form and submit it to NAPRA as soon as possible. All applications for Interested Party status must be submitted in writing to the NDSAC Secretariat via email no later than 4:00 p.m. (ET) on Thursday, January 19, 2023.
Alternate Method of Participation
Individuals, companies or organizations who chose not to pursue Interested Party status or have been denied the status can provide comments, in writing, related to the agenda item outlined above. The comments must be received by the NDSAC Secretariat via email no later than 4:00 p.m. (ET) on Friday, February 24, 2023. Please note: only an acknowledgement of receipt for the comments received will be provided. All comments or information provided by this alternate method of participation shall be provided to NAPRA and any person, association or other entity that has obtained Interested Party status. For more information, please contact the NDSAC Secretariat via email at [email protected].
Subscribe to Updates from NAPRA
Receive NAPRA updates of interest directly to your inbox: general NAPRA news, NDS updates and/or updates on practice resources.